Overview
Most people who start semaglutide or tirzepatide are thinking about the scale, their blood sugar, or their heart. This month, one of the world's top scientific journals asked a different question: what are these drugs doing to the brain? In a new review published in Science, researchers from the University of Gothenburg and the University of Copenhagen pulled together the evidence on GLP-1 medications and cognition — memory, attention, planning, and long-term dementia risk. The picture that emerges is genuinely interesting: promising signals in some places, a high-profile disappointment in another, and a clear message about who might stand to benefit. Here's what the review found, and what it means if you're taking or considering a GLP-1.

